The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2

Histopathology

Volumn 43, Issue 3, 2003, Pages 231-238

  Attanoos, R L ^a   Griffin, A ^a   Gibbs, A R ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Bcl 2; Desmin; Epithelial membrane antigen; Immunohistochemistry; Malignant mesothelioma; P glycoprotein; p53; Platelet derived growth factor receptor; Reactive mesothelial hyperplasia

Indexed keywords

AVIDIN; BIOTIN; DESMIN; EPITHELIAL MEMBRANE ANTIGEN; GLYCOPROTEIN P; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CA-15-3 ANTIGEN; DESMIN; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; P-GLYCOPROTEIN; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141613691     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01686.x     Document Type: Article

References (34)

1. Enzinger FM, Weiss SW. In Enziger FM and Weiss S eds. Soft tissue tumours, 3rd edn. St Louis: Mosby, 1995: 787-819.
2. Churg A, Colby TV, Cagle P et al. The separation of benign and malignant mesothelial proliferations. Am. J. Surg. Pathol. 2000; 24: 1183-1200.
3. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology 1997; 30: 403-418.
4. Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue. Am. J. Surg. Pathol. 1986; 10: 34-47.
5. McCaughey WTE, Al-Jabi M. Differentiation of serosal hyperplasia and neoplasia in biopsies. Pathol. Annu. 1986; 21: 271-293.
6. Mangano WE, Cagle PT, Churg A et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am. J. Clin. Pathol. 1998; 110: 191-199.
7. Wolanski KD, Whitaker D, Shilkin KB et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 1998; 82: 583-590.
8. Casalots J, Tarroch X, Forcada P et al. Utility of epithelial membrane antigen and p53 in the differential diagnosis of benign reactive processes from malignancy in pleural biopsy specimens. Virchows Arch. 1999; 435: 286.
9. Cury PM, Butcher DN, Corrin B et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J. Pathol. 1999; 189: 251-257.
10. Walts AE, Said JW, Shintaku IP. Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: immunocytochemical and ultrastructural localisation in benign and malignant cells. Diagn. Cytopathol. 1987; 3: 41-49.
11. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000; 11: 8-17.
12. Roberts F, Harper CM, Downie I et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. Am. J. Clin. Pathol. 2001; 116: 253-262.
13. Kafiri G, Thomas DM. Shepherd NA et al. p53 expression is common in malignant mesothelioma. Histopathology 1992; 21: 331-334.
14. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J. Pathol. 1992; 168: 377-381.
15. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum. Pathol. 1994; 25: 443-448.
16. Ramael M, Lemmens G, Eerdekens C et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J. Pathol. 1992; 168: 371-375.
17. Esposito V, Baldi A, De Luca A et al. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res. 1997; 17: 733-736.
18. Ramael M, Buysse C, Van Den Bossche J et al. Immunoreactivity for the β chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J. Pathol. 1992; 167: 1-4.
19. Ramael M, Van Den Bossche J, Buysse C et al. Immunoreactivity for P-170 glycoprotein in malignant and in non-neoplastic mesothelium of the pleura arising the murine monoclonal antibody JSB-1. J. Pathol. 1992; 167: 5-8.
20. Segers K, Ramael M, Kumar Singh S et al. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch. 1994; 242: 631-634.
21. Mayall FG, Goddard H, Gibbs AR. Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon. Histopathology 1992; 21: 453-457.
22. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum. Pathol. 1994; 25: 753.
23. Scoones DJ, Richman PI. Expression of desmin and smooth muscle actin in mesothelial hyperplasia and mesothelioma. J. Pathol. 1993; 169S: 188A.
24. Doglioni C, Dei Tos AP, Lorino L et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am. J. Surg. Pathol. 1996; 20: 1037-1046.
25. Clover J, Oates J, Edwards C. Anticytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31: 140-143.
26. Azumi N, Ben-Ezra J, Battifora H. Immunophenotypic diagnosis of leiomyosarcomas and rhabdomyosarcomas with monoclonal antibodies to muscle-specific actin and desmin in formalin-fixed tissue. Mod. Pathol. 1988; 1: 469.
27. Parham DM, Dias P, Kelly DR et al. Desmin positivity in primitive neuroectodermal tumours of childhood. Am. J. Surg. Pathol. 1992; 16: 483.
28. Folpe AL, Patterson K, Gown AM. Antibodies to desmin identified the blastemal component of neuroblastoma. Mod. Pathol. 1997; 10: 895.
29. Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumour pathology. Cancer 1981; 47: 1786-1795.
30. Lane DP. Benchimol S. p53: oncogene or antioncogene? Genes Dev. 1990; 4: 1-8.
31. Lu Q, Abel P, Foster CS et al. Bcl-2: role in epithelial differentiation and oncogenesis. Hum. Pathol. 1996; 27: 102-110.
32. Narasimhan SR, Yang L, Gerwin BI et al. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of bcl-2 and bax. Am. J. Physiol. 1998; 275: L165-L171.
33. Willingham MC, Richert ND, Cornwell MM et al. Immunocytochemical localisation of P-170 at the plasma membrane of multidrug resistant human cells. J. Histochem. Cytochem. 1987; 35: 1451-1456.
34. Garlepp MJ, Christmas TI, Manning LS et al. The role of platelet derived growth factor in the growth of human malignant mesothelioma. Eur. Resp. Rev. 1993; 3: 189-191.